05 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: AtCor Medical, the developer and marketer of the SphygmoCor system which measures central aortic blood pressures and arterial stiffness noninvasively, has got approval for its SphygmoCor XCEL system by the Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris), the authority that regulates medical devices in Mexico. This enables BCR Internacional, AtCor's Mexican distributor, to market and sell the system to clinicians and researchers in Mexico.
Mr Duncan Ross, CEO, AtCor Medical, said that: "Mexico is an important market for AtCor. The SphygmoCor XCEL system provides an opportunity to incorporate measurement of central aortic blood pressure into patient management and to positively impact healthcare in the Mexican population."
He further added, "The opportunity for countries such as Mexico to implement programs that identify patients at risk, educate them to modify their lifestyles and seek treatment ahead of critical incidents is important to governments for both its economic and quality of life implications. SphygmoCor XCEL is well positioned to provide this information in a cost effective manner."
Mr Enrique Cerrillo Romero, general manager, BCR Internacional, AtCor's Mexico distributor, said that, "We are very pleased to have achieved SphygmoCor XCEL registration and look forward to marketing this innovative and important technology to clinicians and researchers throughout Mexico. Interest during our premarketing period has been very strong."
Mexico is the second largest medical device market in Latin America with an estimated annual market of $4 billion. It has a population of 113 million, and a large proportion of Mexican adults have risk factors for heart disease and stroke. According to a 2010 study of 20,000 Mexican adults published in American Heart Journal, hypertension affected almost 30 percent of adults and about 13 percent of adults had diabetes.